Lipgloss and Aftershave
NOVEMBER 25, 2024
Video Recap of AAAM (American Academy of Aesthetic Medicine) L+A attended AAAM Orlando on November 8th and 9th, where L+A Medical Editor, Dr. Chantal Lunderville was presenting. We had the opportunity to interview seven physicians who are part of the AAAM International Faculty. We’ve created a compilation of all of these interviews to share with the L+A Community.
US Dermatologt Partners
NOVEMBER 25, 2024
While melanoma is a relatively rare form of skin cancer, the number of melanoma cases diagnosed has increased over the past several decades. Despite more overall cases, the melanoma mortality rate has decreased, in part due to earlier diagnosis. According to Dr. Yanes of U.S. Dermatology Partners Annapolis , “Early diagnosis is key to successfully treating melanoma.
Dermatology Times
NOVEMBER 25, 2024
Panelists discuss how setting long-term treatment goals for basal cell carcinoma (BCC) patients involves balancing factors such as disease control, quality of life, and potential adverse reactions to create personalized management plans that address both immediate concerns and future outcomes.
The Dermatology Digest
NOVEMBER 25, 2024
Jerry Tan, MD, is joining Derm-Biome Pharmaceuticals, Inc.’s Scientific Advisory Board. Dr. Jerry Tan, is a dermatologist in Windsor, ON, the immediate past President of the Acne and Rosacea Society of Canada, co-chair of the Acne Core Outcomes Research Network (ACORN), Derm-Biome Pharmaceuticals develops topical treatments for acne, atopic dermatitis, and precancerous skin conditions.
Dermatology Times
NOVEMBER 25, 2024
Catch up on coverage from the 22nd annual Society of Dermatology Physician Associates Fall Dermatology Conference in Las Vegas, Nevada.
Dermatology Times
NOVEMBER 25, 2024
Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
Dermatology Times
NOVEMBER 25, 2024
According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.
Dermatology Times
NOVEMBER 25, 2024
The JAK inhibitor was significantly superior in all safety and efficacy endpoints, when compared to other AA treatment options.
Expert insights. Personalized for you.
52 
Let's personalize your content